GRAIL, Inc. $GRAL Stock: Pictet Asset Management Holding SA Cuts Position

Pictet Asset Management Holding SA lessened its holdings in GRAIL, Inc. (NASDAQ:GRAL – Free Report) by 16.2% during the third quarter, Holdings Channel.com reports. The institutional investor owned 41,939 shares of the company’s stock after selling 8,100 shares during the quarter. Pictet Asset Management Holding SA’s holdings in GRAIL were worth $5,748,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Fifth Third Bancorp increased its position in shares of GRAIL by 15,733.3% during the first quarter. Fifth Third Bancorp now owns 475 shares of the company’s stock valued at $25,000 after acquiring an additional 472 shares during the last quarter. Geneos Wealth Management Inc. lifted its holdings in GRAIL by 160.0% during the first quarter. Geneos Wealth Management Inc. now owns 585 shares of the company’s stock worth $30,000 after acquiring an additional 360 shares during the period. Allworth Financial LP bought a new stake in GRAIL during the second quarter worth $35,000. North Star Investment Management Corp. boosted its position in GRAIL by 809.1% in the third quarter. North Star Investment Management Corp. now owns 300 shares of the company’s stock worth $42,000 after purchasing an additional 267 shares during the last quarter. Finally, Root Financial Partners LLC purchased a new position in GRAIL in the third quarter worth $44,000.

Insider Buying and Selling at GRAIL

In other GRAIL news, insider Andrew Partridge sold 7,873 shares of the firm’s stock in a transaction on Monday, October 5th. The stock was sold at an average price of $146.39, for a total value of $1,152,528.47. Following the completion of the sale, the insider directly owned 155,865 shares of the company’s stock, valued at $22,817,077.35. This trade represents a 4.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Joshua Ofman sold 61,452 shares of the firm’s stock in a transaction on Monday, September 21st. The stock was sold at an average price of $97.74, for a total value of $6,006,318.48. Following the completion of the sale, the chief executive officer directly owned 362,271 shares of the company’s stock, valued at $35,408,367.54. This represents a 14.50% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 129,944 shares of company stock valued at $14,832,805. Company insiders own 1.83% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on GRAL shares. Guggenheim upped their price objective on GRAIL from $75.00 to $155.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Royal Bank Of Canada lifted their target price on GRAIL from $84.00 to $100.00 and gave the stock a “sector perform” rating in a research note on Thursday, November 5th. Morgan Stanley boosted their price target on shares of GRAIL from $60.00 to $120.00 and gave the stock an “equal weight” rating in a report on Monday, October 12th. Mizuho boosted their price target on shares of GRAIL from $65.00 to $100.00 and gave the stock a “neutral” rating in a report on Friday, September 25th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of GRAIL in a research report on Thursday, October 15th. Five research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $128.80.

Get Our Latest Report on GRAL

GRAIL Price Performance

Shares of GRAIL stock traded down $5.46 on Friday, reaching $115.89. 360,786 shares of the company traded hands, compared to its average volume of 936,290. The company has a 50 day moving average of $121.46 and a 200 day moving average of $79.72. GRAIL, Inc. has a 52 week low of $41.50 and a 52 week high of $166.48. The firm has a market capitalization of $5.21 billion, a PE ratio of -12.20 and a beta of 2.86.

GRAIL (NASDAQ:GRAL – Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The company reported ($2.21) EPS for the quarter, topping analysts’ consensus estimates of ($2.45) by $0.24. The company had revenue of $37.53 million for the quarter, compared to analysts’ expectations of $44.21 million. GRAIL had a negative net margin of 243.80% and a negative return on equity of 16.13%. As a group, analysts anticipate that GRAIL, Inc. will post -9.11 earnings per share for the current year.

GRAIL Company Profile

(Free Report)

GRAIL, Inc. is a healthcare company developing blood-based tests for the early detection of multiple cancers. Its approach analyzes patterns in cell-free DNA, including DNA methylation signals, to help identify a possible cancer signal and predict its origin in the body. GRAIL’s flagship product is Galleri, a multi-cancer early detection test intended for use alongside—not as a replacement for—recommended cancer screening. The company also conducts clinical research to evaluate the test and advance its early-detection technology.

See Also

Want to see what other hedge funds are holding GRAL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GRAIL, Inc. (NASDAQ:GRAL – Free Report).

Institutional Ownership by Quarter for GRAIL (NASDAQ:GRAL)

Receive News & Ratings for GRAIL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRAIL and related companies with MarketBeat.com's FREE daily email newsletter.